Clinical trial
Pilot Study of Redirected Autologous T-cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patient With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
NCT01029366 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pilot Study of Redirected Autologous T-cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patient With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
- Lead sponsor
- University of Pennsylvania
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 17, 2010
- Completion date
- May 31, 2016
- Enrollment
- 26 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adult acute lymphoblastic leukemia in remission, b-cell adult acute lymphoblastic leukemia, b-cell chronic lymphocytic leukemia, hematopoietic/lymphoid cancer, prolymphocytic leukemia, recurrent adult diffuse large cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, refractory chronic lymphocytic leukemia, stage iii adult diffuse large cell lymphoma, stage iii chronic lymphocytic leukemia, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iv adult diffuse large cell lymphoma, stage iv chronic lymphocytic leukemia, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma